Moderna shares jump on cancer‑vaccine news and Nasdaq‑100 inclusion
Moderna Inc. stock rose sharply on October 14, 2026 after the U.S. NIH announced a new public‑private initiative to fast‑track therapeutic cancer vaccines, aligning with the company’s oncology program. The biotech also entered the Nasdaq‑100 index on October 9, replacing Warner Bros. Discovery, which adds passive‑investment demand. For the quarter, Moderna reported revenue of $143 million, a net loss of $782 million, and held about $5.14 billion in cash and short‑term investments. Bank of America lifted its price target to $200 and Morgan Stanley to $95, while the next earnings release is scheduled for November 6, 2026.
Why it matters
The Nasdaq‑100 addition creates forced buying from index funds, supporting short‑term demand. Bank of America’s higher target reflects expectations that the NIH cancer‑vaccine push could improve future revenue.
Key facts
- 1Moderna’s Q2 2026 revenue was $143 million. stockstotrade.com
- 2The company posted a net loss of $782 million for the quarter. stockstotrade.com
- 3Cash, cash equivalents and short‑term investments total about $5.14 billion. stockstotrade.com
- 4Moderna joined the Nasdaq‑100 index on 2026/10/09, replacing Warner Bros. Discovery. stockstotrade.com
- 5Bank of America raised its price target for Moderna to $200. stockstotrade.com
- 6Morgan Stanley raised its price target for Moderna to $95. stockstotrade.com
Open questions
- Material 1 reports a 4.22% price increase while material 2 reports a 4.13% increase on the same day.
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.